Covaxin Phase 3 clinical trial shows 81% efficacy

India’s first indigenously produced Covid-19 vaccine has been developed jointly by the ICMR and Bharat Biotech

geetanjali

Geetanjali Minhas | March 4, 2021 | Mumbai


#healthcare   #Novel Coronavirus   #Covid-19   #vaccination   #Covaxin   #ICMR   #bharat Biotech   #DGCI  


India’s first indigenously produced Covid-19 vaccine, Covaxin, has shown an interim efficacy of 81% in Phase III trials for preventing the virus. Covaxin has been developed in India jointly by the Indian Council of Medical Research (ICMR) along with Bharat Biotech International Limited (BBIL).        

The Phase III trial was initiated by ICMR and BBIL in mid-November 2020 and it was conducted on a total of 25,800 individuals across 21 sites. The interim efficacy of 81%, analyzed as per the protocol approved by the Drugs Controller General of India (DCGI), puts it at par with other global front-runner vaccines.

The initial interim analysis of Phase III trial data is based on 43 cases of Covid-19 of which 36 cases of Covid-19 were observed in the placebo group and 7 cases observed in the Covaxin group resulting in a point estimate of vaccine efficacy of 80.6 percent.

Bharat Biotech expects to get a clearer picture of its efficacy once 130 cases are accumulated among its participants. Phase 1 and Phase 2 clinical trials were conducted on 755 participants and demonstrated high safety profile of the candidate vaccine with seroconversion rates of 98.3% and 81.1% on day 56 and 104 respectively.

The results have been evaluated by an independent data safety and monitoring board show that the vaccine is well-tolerated and efficacious against SARS-CoV-2 across a wide range of age groups and variants in the country.

In March 2020, following the successful isolation of the SARS CoV-2 virus at ICMR-National Institute of Virology (NIV), ICMR entered into a public-private partnership with BBIL to develop the virus isolate into an effective vaccine candidate. ICMR-NIV characterized the vaccine developed by BBIL through in-vitro experiments and electron microscopy studies. Pre-clinical studies in small animals and hamsters showed promising results for safety and immunogenicity. Further studies conducted in rhesus macaques also established remarkable safety and protective efficacy of Covaxin.

“Covaxin has been developed on WHO prequalified vero cell platform globally recognized with a well-established track record of safety. Covaxin’s ability to neutralize UK variant strain of SARS-CoV-2 has also recently been established,” the ICMR said in its statement.

“The bench-to-bedside journey of completely indigenous Covid-19 vaccine in less than 8 months’ time showcases immense strength of Atmanirbhar Bharat [self-reliant India] to fight the odds and stand tall in the global public health community. It is also a testament to India’s emergence as a global vaccine superpower,” said Dr. Balram Bhargava, director general, ICMR.

“Covaxin demonstrated 81 percent interim efficacy in preventing Covid-19 in those without prior infection after the second dose. Data from 25,800 participants who received a vaccine or placebo in a 1:1 ratio showed that the vaccine candidate was well tolerated,” BBL said in its statement.

According to the Hyderabad-based vaccine maker, inclusion of the Algel-IMDG adjuvant in the vaccine enhances T-cell immune responses to Covid-19 leading to long-term protection. The vaccine has been approved for restricted emergency use under clinical trial mode and will have to be taken in two doses 28 days apart.

“With today’s results from our Phase 3 trials we have now reported data on our Covid-19 vaccine from Phase 1, 2 and 3 trials involving around 27,000 participants. Covaxin also demonstrates significant immunogenicity against the rapidly emerging variants,” said Dr Krishna Ella, chairman and manging director, Bharat Biotech.

Covaxin Timeline:
March 11, 2020: Covid-19 was declared a pandemic by the WHO. India joined the global race of developing safe and effective vaccines to protect its citizens as well as the global community from this dreaded disease.
• March 13, 2020: ICMR-National Institute of Virology (ICMR-NIV) successfully isolates the SARSCoV-2 virus. India becomes the 5th country in the world to achieve this feat.
• April 2020: ICMR enters into a public-private partnership with Bharat Biotech International Ltd (BBIL) for developing an effective vaccine candidate for SARS-CoV-2.
• May 2020: ICMR-NIV transfers the virus strain to BBIL and characterizes the vaccine developed by BBIL through in-vitro experiments and electron microscopy studies.
• June-August 2020: Experiments in small animals (mouse, rats and rabbits) and hamsters established promising safety and immunogenicity of COVAXIN. Data has been published by the highly reputed journal of the Cell Press.
• July-August 2020: Studies conducted in rhesus macaques established safety and protective efficacy of Covaxin. Results established the remarkable ability of the vaccine candidate to clear the virus from infected organs along with its capacity to mount B and T cell immune response.
• July-October 2020: Phase 1 and 2 clinical trials conducted in 755 participants demonstrated a high safety profile of the candidate vaccine along with seroconversion rates of 98.3% and 81.1% respectively on day 56 and 104 respectively. The results are published in Lancet's journal.
• November 2020: The largest ever clinical trial for COVID-19 in India launched for the third phase with over 25,800 participants
• January 3, 2021: DCGI grants approval for restricted use in emergency situations for COVAXIN
• January 16, 2021: India rolls-out phase-wise COVID-19 vaccine administration starting with healthcare and frontline workers
• January 27, 2021: COVAXIN’s ability to neutralize UK variant strain of SARS-CoV-2 established and published in Journal of Travel Medicine.
• March 3, 2021: Interim results of Phase 3 efficacy trials of COVAXIN show 81% efficacy against SARS-CoV-2virus. The follow-up of participants in the trial are still ongoing.


 

Comments

 

Other News

Non-vaccinated staff allowed mandatory rapid antigen tests

Maharashtra has modified guidelines on restrictions imposed to curb the spread of Covid-19, and put out clarifications on do Do’s and Don’ts to be followed under its ‘Break the Chain’ orders.   Starting Saturday, Rapid Antigen Tests are allowed for non-vaccinated

Probe agencies` credibility in doubt: Prithviraj Chavan

Raising concerns about the “leaks” of aspects of an ongoing investigation into incidents leading to political turmoil in Maharashtra, former chief minister and senior Congress leader Prithviraj Chavan has said the NIA is selectively leaking info on the case and it is a serious matter. &n

On vaccine shortage, Maharashtra hits back at centre

Maharashtra, suffering from a heavy number of fresh cases every day and complaining of vaccine shortage, has replied to the union health minister criticism and blamed the centre for the situation. “Union Health Minister Shri Harsh Vardhan ji needs to be reminded that Maharashtra tops t

Mumbai allows 24x7 delivery of essential services

Amid tighter movement restrictions as the city and the state continue to battle a consistently rising trajectory of fresh Covid-19 cases, Mumbai civic authorities on Thursday allowed 24-hour home deliveries of food and essential supplies through online service providers like Zomato and Swiggy on all days o

Maharashtra, centre trade charges as India reports highest ever cases

India recorded a new high of 1,15,736 daily Covid-19 cases with Maharashtra bearing nearly half of the load, as the state and the centre traded charges for the first time since the outbreak. State leaders sought to put part of the blame on the centre while union health minister Dr Harsh Vardhan slammed the

Deshmukh likely to challenge high court order in SC

Anil Deshmukh is reportedly considering approaching the supreme court Tuesday to challenge a Bombay high court order that had forced him to quit as home minister of Maharashtra a day earlier. Deshmukh tendered his resignation to governor Bhagat Singh Koshyari, citing moral grounds, after the

Visionary talk with Prithviraj Chavan, On the need for vaccination & Maha Political volcano



Archives

Current Issue

Opinion

Facebook    Twitter    Google Plus    Linkedin    Subscribe Newsletter

Twitter